Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at the Revolutionizing Atopic Dermatitis Conference, Nashville, US, on 7 June, highlighting the impact of Dupixent (dupilumab) in patients with moderate-to-severe atopic dermatitis (AD) and skin of colour. The open-label trial enrolled 120 patients with Fitzpatrick skin types IV–VI, including Black, […]
The post Dupixent improves symptoms in patients with skin of colour, study shows appeared first on Pharmafile.
